Literature DB >> 22168396

Diurnal variation of phenylalanine concentrations in tyrosinaemia type 1: should we be concerned?

A Daly1, H Gokmen-Ozel, A MacDonald, M A Preece, P Davies, A Chakrapani, P McKiernan.   

Abstract

BACKGROUND: Tyrosinaemia type 1 (HT1) is treated with a tyrosine and phenylalanine-restricted diet, amino acids free of phenylalanine and tyrosine, and nitisinone (NTBC). Treatment guidelines recommend plasma tyrosine between 200-400 μm and phenylalanine at least >30 μm. There is little information on the diurnal variation of plasma tyrosine or phenylalanine in HT1. Low plasma phenylalanine <30 μm may be associated with poor growth and cognitive delay. The present study aimed to document diurnal variation of tyrosine and phenylalanine plasma concentrations and growth in children with HT1.
METHODS: Median tyrosine and phenylalanine plasma concentrations were reviewed retrospectively over 3 years in 11 subjects (median age 4 years) with HT1. Subjects routinely collected morning fasting blood samples but afternoon nonfasted samples were taken in the clinic (<10% of samples). Growth Z-scores were calculated.
RESULTS: The percentage of all plasma phenylalanine concentrations <30 μm was 8.6% and <40 μm was 13.6%. Only 2% of fasting morning phenylalanine concentrations were <30 μm, compared to 83% of nonfasting afternoon samples. All but one child had a height Z-score <0.
CONCLUSIONS: Blood phenylalanine concentrations were consistently lower in the afternoon. Taking blood samples at variable time points in the day may lead to variation in interpreting dietary control. A detailed study is necessary to examine the 24-h diurnal variation of plasma phenylalanine and tyrosine in HT1. It is possible that phenylalanine concentrations may be very low for a substantive time over 24 h and the potential impact that this may have on cognitive development and growth in children is unknown.
© 2011 The Authors. Journal of Human Nutrition and Dietetics © 2011 The British Dietetic Association Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22168396     DOI: 10.1111/j.1365-277X.2011.01215.x

Source DB:  PubMed          Journal:  J Hum Nutr Diet        ISSN: 0952-3871            Impact factor:   3.089


  15 in total

1.  Infants with Tyrosinemia Type 1: Should phenylalanine be supplemented?

Authors:  Danique van Vliet; Esther van Dam; Margreet van Rijn; Terry G J Derks; Gineke Venema-Liefaard; Marrit M Hitzert; Roelineke J Lunsing; M Rebecca Heiner-Fokkema; Francjan J van Spronsen
Journal:  JIMD Rep       Date:  2014-09-26

2.  What Is the Best Blood Sampling Time for Metabolic Control of Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients?

Authors:  Esther van Dam; Anne Daly; Gineke Venema-Liefaard; Margreet van Rijn; Terry G J Derks; Patrick J McKiernan; M Rebecca Heiner-Fokkema; Anita MacDonald; Francjan J van Spronsen
Journal:  JIMD Rep       Date:  2017-01-25

3.  Serum Amino Acid Profiling in Patients with Alkaptonuria Before and After Treatment with Nitisinone.

Authors:  A S Davison; B P Norman; E A Smith; J Devine; J Usher; A T Hughes; M Khedr; A M Milan; J A Gallagher; L R Ranganath
Journal:  JIMD Rep       Date:  2018-05-13

4.  Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls.

Authors:  Willem G van Ginkel; Rianne Jahja; Stephan C J Huijbregts; Anne Daly; Anita MacDonald; Corinne De Laet; David Cassiman; François Eyskens; Irene M L W Körver-Keularts; Philippe J Goyens; Patrick J McKiernan; Francjan J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2016-06-29       Impact factor: 4.123

5.  Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1.

Authors:  Willem G van Ginkel; Danique van Vliet; Johannes G M Burgerhof; Pim de Blaauw; M Estela Rubio Gozalbo; M Rebecca Heiner-Fokkema; Francjan J van Spronsen
Journal:  PLoS One       Date:  2017-09-26       Impact factor: 3.240

Review 6.  Nutrition in Chronic Liver Disease: Consensus Statement of the Indian National Association for Study of the Liver.

Authors:  Pankaj Puri; Radha K Dhiman; Sunil Taneja; Puneeta Tandon; Manuela Merli; Anil C Anand; Anil Arora; Subrat K Acharya; Jaya Benjamin; Yogesh K Chawla; Sunil Dadhich; Ajay Duseja; C E Eapan; Amit Goel; Naveen Kalra; Dharmesh Kapoor; Ashish Kumar; Kaushal Madan; Aabha Nagral; Gaurav Pandey; Padaki N Rao; Sanjiv Saigal; Neeraj Saraf; Vivek A Saraswat; Anoop Saraya; Shiv K Sarin; Praveen Sharma; Akash Shukla; Sandeep S Sidhu; Namrata Singh; Shivaram P Singh; Anshu Srivastava; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2020-10-01

Review 7.  Recommendations for the management of tyrosinaemia type 1.

Authors:  Corinne de Laet; Carlo Dionisi-Vici; James V Leonard; Patrick McKiernan; Grant Mitchell; Lidia Monti; Hélène Ogier de Baulny; Guillem Pintos-Morell; Ute Spiekerkötter
Journal:  Orphanet J Rare Dis       Date:  2013-01-11       Impact factor: 4.123

Review 8.  Single amino acid supplementation in aminoacidopathies: a systematic review.

Authors:  Danique van Vliet; Terry G J Derks; Margreet van Rijn; Martijn J de Groot; Anita MacDonald; M Rebecca Heiner-Fokkema; Francjan J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2014-01-13       Impact factor: 4.123

9.  Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.

Authors:  Sebene Mayorandan; Uta Meyer; Gülden Gokcay; Nuria Garcia Segarra; Hélène Ogier de Baulny; Francjan van Spronsen; Jiri Zeman; Corinne de Laet; Ute Spiekerkoetter; Eva Thimm; Arianna Maiorana; Carlo Dionisi-Vici; Dorothea Moeslinger; Michaela Brunner-Krainz; Amelie Sophia Lotz-Havla; José Angel Cocho de Juan; Maria Luz Couce Pico; René Santer; Sabine Scholl-Bürgi; Hanna Mandel; Yngve Thomas Bliksrud; Peter Freisinger; Luis Jose Aldamiz-Echevarria; Michel Hochuli; Matthias Gautschi; Jessica Endig; Jens Jordan; Patrick McKiernan; Stefanie Ernst; Susanne Morlot; Arndt Vogel; Johannes Sander; Anibh Martin Das
Journal:  Orphanet J Rare Dis       Date:  2014-08-01       Impact factor: 4.123

Review 10.  Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.

Authors:  Jeffrey M Chinsky; Rani Singh; Can Ficicioglu; Clara D M van Karnebeek; Markus Grompe; Grant Mitchell; Susan E Waisbren; Muge Gucsavas-Calikoglu; Melissa P Wasserstein; Katie Coakley; C Ronald Scott
Journal:  Genet Med       Date:  2017-08-03       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.